← Back to Home

Dual-pathway treatment for Crohn’s disease: ABBV-466 shows higher endoscopic remission rates in Phase 2 trial

Can simultaneously inhibiting inflammatory signals and immune cell entry into the gut improve on monotherapy? A 300-patient trial showed positive signals, but statistical evidence and long-term safety data remain incomplete.

By SURL BioNews

For patients with Crohn’s disease, less abdominal pain and diarrhea do not necessarily mean intestinal inflammation has subsided. Achieving better control of inflammation in the intestinal lining is an important test for new therapies. On October 19, AbbVie announced early Phase 2 trial results showing that its dual-targeted therapy ABBV-466 achieved a higher endoscopic remission rate than either of two monotherapies, providing preliminary clinical support for simultaneously targeting two immune pathways.

ABBV-466 combines two antibodies: risankizumab inhibits the p19 subunit of IL-23, while trosunilimab targets integrin α4β7. Under the company’s development rationale, the former suppresses inflammatory signals, while the latter limits immune cell migration to the gut, seeking to control disease through complementary mechanisms. This is a strategy combining two drugs, rather than a single bispecific antibody.

The newly announced TARGET-CD analysis included 300 patients with moderately to severely active Crohn’s disease. The ClinicalTrials.gov registration confirms that this is a randomized, open-label, early Phase 2 platform trial with risankizumab monotherapy, trosunilimab monotherapy, and combination treatment arms. The platform also includes other treatment arms, so these results from 300 patients do not mean the entire platform study has been completed.

At the primary assessment time point of Week 12, 30.2% of patients in the ABBV-466 group achieved endoscopic remission, compared with 21.3% in the risankizumab group and 18.0% in the trosunilimab group. The differences were 8.9 and 12.2 percentage points, respectively. According to the trial registration, remission requires central confirmation of a Simple Endoscopic Score for Crohn’s Disease (SES-CD) of no more than 4, with no individual score exceeding 1. This measure assesses lesions in the intestinal lining and differs from whether patients report an improvement in symptoms.

The company also reported that at Week 24, the endoscopic remission rate in the combination treatment group rose to 40.5%, compared with 22.4% and 20.0% in the two monotherapy groups, respectively. The numerical differences widened with follow-up, providing a reason to continue studying this strategy. However, the announcement did not provide confidence intervals or p-values for comparisons between groups, so the differences in rates alone cannot establish statistically demonstrated superiority.

Regarding safety, the proportion of patients with serious adverse events was 10.4% in the ABBV-466 group, compared with 9.6% and 9.0% in the two monotherapy groups, respectively. These events were not necessarily caused by the drugs, and similar proportions are insufficient to demonstrate that combination treatment has the same safety profile. An early trial of 300 patients and the current follow-up duration remain insufficient to fully identify rare risks or those that emerge only after long-term use.

The efficacy results currently come primarily from the company’s announcement. The trial registration allows the study structure and assessment methods to be checked, but does not independently verify these results. The open-label design is another limitation when interpreting the findings. ABBV-466 remains an investigational therapy. These data support further validation, but more complete clinical evidence is still needed to determine whether it can deliver lasting remission and to assess the overall benefits and risks of adding another drug.

References

  1. AbbVie
  2. ClinicalTrials.gov